Oncotarget · 2015 · 26 citations · 45 references
Life SciencesMolecular BiologyPharmacologyCell SignalingInflammationSignal TransductionCytokine SignalingInflammatory Cell ResponsesInflammatory Response RegulationInflammatory SignalingCellular Inflammatory ResponsesInflammatory Pathway DysregulationInflammatory Signaling DysregulationNuclear Factor Kappa B Signaling Genetics
// Ting Li 1,* , Vincent Kam Wai Wong 1,* , Zhi Hong Jiang 1 , Shui Ping Jiang 1 , Yan Liu 2 , Ting Yu Wang 2 , Xiao Jun Yao 1 , Xiao Hui Su 1 , Feng Gen Yan 1 , Juan Liu 1 , Elaine Lai-Han Leung 1 , Xiao Qin Yi 2 , Yuen Fan Wong 2 , Hua Zhou 1 and Liang Liu 1 1 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China 2 Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China * These authors contributed equally to this work Correspondence to: Liang Liu, email: // Hua Zhou, email: // Keywords : cysteine mutation, dihydromyricetin, IKK-β inhibitor, inflammation, NF-κB Received : April 15, 2015 Accepted : August 13, 2015 Published : September 10, 2015 Abstract Activation of IκB kinase β (IKK-β) and nuclear factor (NF)-κB signaling contributes to cancer pathogenesis and inflammatory disease; therefore, the IKK-β−NF-κB signaling pathway is a potential therapeutic target. Current drug design strategies focus on blocking NF-κB signaling by binding to specific cysteine residues on IKK-β. However, mutations in IKK-β have been found in patients who may eventually develop drug resistance. For these patients, a new generation of IKK-β inhibitors are required to provide novel treatment options. We demonstrate in vitro that cysteine-46 (Cys-46) is an essential residue for IKK-β kinase activity. We then validate the role of Cys-46 in the pathogenesis of inflammation using delayed-type hypersensitivity (DTH) and an IKK-β C46A transgenic mouse model. We show that a novel IKK-β inhibitor, dihydromyricetin (DMY), has anti-inflammatory effects on WT DTH mice but not IKK-β C46A transgenic mice. These findings reveal the role of Cys-46 in the promotion of inflammatory responses, and suggest that Cys-46 is a novel drug-binding site for the inhibition of IKK-β.
45
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +15
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Dongsheng Cai, Minsheng Yuan, Daniel Frantz et al. · Nature Medicine · 2005 · 2.2K citations · Full text
IKK-β links inflammation to obesity-induced insulin resistance
Melek C. Arkan, Andrea L. Hevener, Florian R. Greten et al. · Nature Medicine · 2005 · 1.8K citations
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Antonio Rossi, Pankaj Kapahi, Gioacchino Natoli et al. · Nature · 2000 · 1.3K citations